The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

Journal of clinical pharmacology

Volumn 54, Issue 12, 2014, Pages 1354-1361

  Shi, Jack G ^a   Chen, Xuejun ^a   Lee, Fiona ^a   Emm, Thomas ^a   Scherle, Peggy A ^a   Lo, Yvonne ^a   Punwani, Naresh ^a   Williams, William V ^a   Yeleswaram, Swamy ^a  

^a Clinical Development   (United States)

Author keywords

baricitinib; JAK; pharmacodynamics; pharmacokinetics; rheumatoid arthritis

Indexed keywords

AZETIDINE DERIVATIVE; BARICITINIB; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; SULFONAMIDE;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FOOD DRUG INTERACTION; HUMAN; MALE; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES; YOUNG ADULT;

EID: 84964315361     PISSN: None     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.354     Document Type: Article

References (0)